To understand functional consequences of genetic and transcriptional aberrations in
prostate cancer, the proteomic changes during disease formation and progression need to …

Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis
of proteomic alterations during cancer progression has been a more daunting task. Here, we …

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate
cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic …

Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …

Despite recent developments in treatment strategies, castration-resistant prostate cancer
(CRPC) is still the second leading cause of cancer-associated mortality among American …

Background Genomic analyses of hundreds of prostate tumors have defined a diverse
landscape of mutations and genome rearrangements, but the transcriptomic effect of this …

Comprehensive genomic studies have delineated key driver mutations linked to disease
progression for most cancers. However, corresponding transcriptional changes remain …

Although prostate cancer (PCa) is the second leading cause of cancer death among men
worldwide, not all men diagnosed with PCa will die from the disease. A critical challenge …

We used clinical tissue from lethal metastatic castration-resistant prostate cancer (CRPC)
patients obtained at rapid autopsy to evaluate diverse genomic, transcriptomic, and …

It remains unclear to what extent tumor heterogeneity impacts on protein biomarker
discovery. Here, we quantified proteome intra-tissue heterogeneity (ITH) based on a multi …